What Brinter does

Brinter, Inc. is a US-incorporated medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair and adjacent applications. Founded in Turku, Finland in 2018 by Tomi Alapaattikoski and Tomi Kalpio, the company relocated its headquarters to Santa Monica, California in 2021 after completing its core platform and securing a €1.2M seed round led by Innovestor. The company's foundation is a proprietary medical-grade multi-material 3D bioprinting platform developed over more than eight years and protected by 10 patents; the platform can print any material, viscosity, and temperature in a single construct and supports closed-loop manufacturing from raw material preparation through final sterilization. Brinter holds this platform exclusively for its own implant portfolio and does not sell or license the technology.

The company's commercial focus is its lead BioMod rotator cuff implant — a bioinductive augmented implant for tissue reinforcement targeting a Q1/2028 US launch and claimed to deliver 3X the strength, 26% better regenerative structure, and 68% fewer failures versus suture-only repair. Beyond the lead product, Brinter is building a pipeline spanning breast reconstruction, ACL, Achilles, meniscus, articular cartilage, nasal, genital, limb, and spinal disc implants across orthopedic, aesthetic, and reconstructive surgery verticals. All products are investigational devices that have not been approved for commercial use in any country. Distribution is planned through direct enterprise engagement with surgeons and medical institutions, supported by a Surgeon Advisory Board of seven named key opinion leaders.

Revenue mechanics are not yet in place: the company is pre-commercial, pricing is not publicly disclosed, and total disclosed capital stands at roughly $4.5M of equity investment plus $6.5M in grants. Strategic partnerships with the Wake Forest Institute for Regenerative Medicine (since 2022), Techstars (2024 graduate), and Plug and Play (2025 graduate), together with TIME Magazine Best Inventions 2025 recognition, anchor credibility as the company prepares its FDA regulatory pathway.

Name

Brinter

Legal name

Brinter, Inc.

Website

https://brinter.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Brinter is a US medtech company developing 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair, using a proprietary multi-material bioprinting platform. Its lead BioMod rotator cuff implant is investigational and targeted for Q1/2028 US commercial launch.

Ownership category

akta.pro rank

Product category

Regenerative Medical Implants

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

3D Bioprinting & Biofabrication (HLAAAGAC)

akta.pro secondary industries

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

Keywords

• 3D bioprinting
• Regenerative implants
• Orthopedic devices
• Tissue engineering
• Medical device manufacturing

Headquarters

HQ city

Winston Salem

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Regenerative Implant Sales: Brinter is approaching commercialization of the first-ever 3D bioprinted regenerative implant in the United States. The company manufactures medical-grade implants for orthopedic and aesthetic applications. Their implants are investigational devices not yet approved for commercial use in any country.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Brinter develops and manufactures 3D-bioprinted, bio-synthetic regenerative implants for orthopedic soft-tissue repair using its proprietary medical-grade multi-material 3D bioprinting platform. Its flagship product, the BioMod Rotator Cuff Implant, is approaching commercialization with a Q1/2028 target launch, alongside a pipeline of additional orthopedic, aesthetic, and other regenerative implants currently investigational.

Product overview

Brinter offers a proprietary medical-grade 3D bioprinting platform that serves as the core technology for its portfolio of regenerative implants. The platform enables multi-material bioprinting of customizable, bioabsorbable implants tailored for medical applications. The product line includes the BioMod Rotator Cuff Implant (launching Q1/2028), Breast Implant, and additional orthopedic implants (ACL, Achilles, Meniscus, Articular Cartilage) in various pipeline stages, as well as R&D implants (Nasal, Genital, Limb, Spinal Disc). The company maintains closed-loop manufacturing control from raw material preparation through final sterilization, producing investigational devices not yet approved for commercial use.

Differentiator

Problem solved

Functional benefit

Products and services

• BioMod Rotator Cuff Implant Bioinductive augmented implant for rotator cuff reinforcement that supports healing, promotes tissue regeneration, and provides strength; reported to be 3X stronger, deliver 26% better regenerative structure, and achieve 68% fewer failures versus suture-only repair. For orthopedic surgeons and their patients with rotator cuff injuries.
• Breast Implant 3D bioprinted regenerative breast implant designed to restore natural shape, softness, and tissue integration following mastectomy. For reconstructive surgeons and post-mastectomy patients.
• ACL Implant Regenerative 3D bioprinted implant for anterior cruciate ligament repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring ACL reconstruction.
• Achilles Implant Regenerative 3D bioprinted implant for Achilles tendon repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring Achilles repair.
• Meniscus Implant Regenerative 3D bioprinted implant for meniscus repair in the orthopedic pipeline. For orthopedic surgeons and patients requiring meniscus treatment.
• Articular Cartilage Implant Regenerative 3D bioprinted implant for articular cartilage repair within the orthopedic pipeline. For orthopedic surgeons and patients requiring articular cartilage restoration.

Quantifiable outcome

• 3X stronger vs suture-only repair
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Wake Forest Institute for Regenerative MedicinecoreStrategic or Co-development PartnerStrategic partnership established in 2022 for collaboration on regenerative medicine research and development. The partnership leverages Wake Forest's expertise in regenerative medicine alongside Brinter's bioprinting technology.
• TechstarsminorStrategic or Co-development PartnerAccelerator program graduate in 2024, providing mentorship, networking, and startup support services.
• Plug and PlayminorStrategic or Co-development PartnerAccelerator program graduate in 2025, providing access to innovation ecosystem and corporate partnerships.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Arthrex: Arthrex is the dominant private orthopedic sports medicine company with deep portfolios in rotator cuff, ACL, meniscus, and Achilles repair, the exact indications Brinter's BioMod and pipeline products target. Arthrex is the primary incumbent Brinter must displace in surgeon adoption.
• BICO (Cellink): BICO, parent of Cellink, is the closest direct peer in 3D bioprinting hardware and consumables for life sciences and medical applications. Comparable as a bioprinting platform company that also pursues regenerative medicine applications.
• Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting technology for regenerative medicine and tissue engineering, including implantable therapeutic tissues. Directly comparable as a peer bioprinting company pursuing regenerative medical applications.
• Organovo: Organovo was a pioneer in 3D bioprinted human tissues for medical research and therapeutic applications. Comparable as a historical direct peer in 3D bioprinting for medical/regenerative use, though now operating at much smaller scale.

Broad incumbents

• Smith+Nephew: Smith+Nephew operates a large sports medicine and orthopedic repair franchise (including REGENETEN bioinductive implants for rotator cuff) that directly competes with Brinter's BioMod and adjacent pipeline. Comparable as a broad incumbent entering the regenerative orthopedic implant space.
• Stryker: Stryker's orthopedic and sports medicine divisions serve the same surgeons and institutions that Brinter targets, with the capital and M&A capacity to acquire or build competing regenerative technologies. Comparable as a broad orthopedic incumbent.
• Integra LifeSciences: Integra LifeSciences has a meaningful regenerative medicine and tissue engineering franchise (e.g., dermal regeneration, dural repair) that overlaps with Brinter's regenerative implant thesis. Comparable as a broad incumbent in regenerative implants.
• CONMED: CONMED's sports medicine portfolio covers rotator cuff, meniscus, and ACL repair instrumentation and implants. Comparable as a broad orthopedic sports medicine incumbent competing for the same surgical accounts.

Emerging players

• Vericel: Vericel commercializes cell therapy and regenerative medicine products (MACI for cartilage repair) and is a relevant comparable as a smaller, commercially focused regenerative medicine company targeting similar orthopedic indications.
• MiMedx: MiMedx develops placental tissue allografts for soft-tissue repair, including applications overlapping with rotator cuff and other orthopedic sports medicine indications. Comparable as an emerging regenerative soft-tissue repair peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/WeAreBrinter

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brinter